Takeda completes $60bn Shire acquisition Pfizer shut two plants in India 1700 jobs at risk BMS to acquire Celgene for $74bn AstraZeneca hire controversial cancer doc NICE rejects Novartis\' Aimovig migraine injection Last week\'s TOP 1

-#Takeda completes $60bn #Shire #acquisition -#Pfizer shut two plants in #India, 1700 #jobs at risk -BMS to acquire Celgene for $74bn -#AstraZeneca hire controversial #cancer doc -NICE rejects Novartis' Aimovig #migraine injection Last week's TOP 1

- #Takeda completes $60bn #Shire #acquisition - #Pfizer shut two plants in #India, 1700 #jobs at risk -BMS to acquire Celgene for $74bn - #AstraZeneca hire controversial #cancer doc -NICE rejects Novartis' Aimovig #migraine injection Last week's TOP 10 http://bit.ly/2M40KSm  pic.twitter.com/YfH38LLQxm

More From BioPortfolio on "-#Takeda completes $60bn #Shire #acquisition -#Pfizer shut two plants in #India, 1700 #jobs at risk -BMS to acquire Celgene for $74bn -#AstraZeneca hire controversial #cancer doc -NICE rejects Novartis' Aimovig #migraine injection Last week's TOP 1"